ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY: Cognitive Impairment II

Top 3 Nutrients to Detox the Liver and Soothe Digestion

Natural Bladder Control, Go Less and Live More

Top Vitamin and Mineral Deficiencies — Are You at Risk?

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Omega Fix for Obesity: How the Right Fats Fight Fat

How Pomegranate May Protect Against Cancer

Trimming the spare tire: Canola oil may cut belly fat

The Onion: Cancer Fighter and Food Preserver

Safely Reduce a Common Cause of Stomach Distress

 
Print Page
Email Article

AIDS vaccine developed at Emory and the NIH Moves to clinical trials

  [ 35 votes ]   [ Discuss This Article ]
www.ProHealth.com • January 24, 2003


A vaccine aimed against AIDS, developed at the Yerkes National Primate Research Center of Emory University, the Emory Vaccine Center, and the Laboratory of Viral Diseases at the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), will begin a Phase I clinical trial this week.

A total of 30 human volunteers will be enrolled at the University of Alabama at Birmingham, the University of Washington in Seattle, and the San Francisco Department of Public Health. The trial is funded by NIAID and is conducted by the HIV Vaccine Trials Network, located at the Fred Hutchinson Cancer Research Center in Seattle, Wash.

Developed by virologists Harriet L. Robinson, PhD, James M. Smith, PhD, Bernard Moss, MD, PhD, and Linda Wyatt, PhD, the vaccine strategy employs two different components: two inoculations of a DNA vaccine that primes the immune system to recognize HIV; and a subsequent booster vaccine based on a recombinant poxvirus. Neither component incorporates the actual virus; instead, the vaccine produces the three major proteins expressed by HIV. In essence, the vaccine induces the immune system to respond to the distinguishing features of HIV so the system will respond to the actual virus should it appear.

This first clinical trial, which will last one year, will focus on assessing the safety of the DNA primer vaccine among HIV-negative volunteers, who will be randomly assigned to receive one of the following: high-dose vaccine, low-dose vaccine, or placebo. A second, separate clinical trial will focus on the safety of the booster vaccine.

"We will have a third Phase I trial to test the combined regimen of the DNA and booster portions of the vaccine strategy," said Dr. Robinson, who is chief of the Yerkes Division of Microbiology and Immunology and a faculty member of the Emory Vaccine Center. As Robinson and her colleagues reported in Science in 2001, in a study involving 24 rhesus macaque monkeys, the prime-boost vaccine strategy successfully contained infection and prevented progression to AIDS. According to a subsequent Yerkes study reported in October 2002 in the Journal of Virology, levels of viral RNA and DNA in the monkeys have declined to the nearly undetectable levels characteristic of a small subset of HIV-infected people, termed long-term non-progressors, who are infected with HIV but do not develop AIDS.

"It is important to remember that this clinical trial represents the culmination of years of work in basic science and preclinical studies involving animal models that have greatly expanded our knowledge of immunology," said Vaccine Center Director Rafi Ahmed, PhD. "Every new AIDS vaccine candidate that enters human studies brings us closer to understanding HIV and the human immune system – and to ending the worldwide AIDS pandemic."

The experimental vaccine is licensed from Emory by GeoVax, Inc., a company founded by Emory University and the Emory Vaccine Center to manufacture the vaccine.


The Yerkes National Primate Research Center of Emory University is one of eight National Primate Research Centers funded by the National Institutes of Health. The Yerkes Center is a multidisciplinary research institute recognized as a leader in biomedical and behavioral studies with non-human primates. Yerkes scientists are on the forefront of developing vaccines for AIDS and malaria, and treatments for cocaine addiction, Parkinson's disease and cardiovascular disease. Other research programs include cognitive development and decline, childhood visual defects, organ transplant rejection and social behaviors of primates. Leading researchers located worldwide seek to collaborate with Yerkes scientists.

The mission of the Emory Vaccine Center is to create new technologies for the prevention of emerging infectious diseases, by conducting basic and translational research and clinical trials. The Vaccine Center was established in 1996 with support from Emory University and the Georgia Research Alliance.

GeoVax, Inc. is developing products related to the research described above. Under an agreement between GeoVax, Inc. and Emory University, the inventors are entitled to a share of sales royalty received by Emory University from GeoVax. Under that agreement, Emory University has received GeoVax equity interests. Dr. Robinson is also Chairman of the Scientific Advisory Board and a minor equity holder in GeoVax. The terms of this arrangement have been reviewed and approved by the University in accordance with its conflict of interest policies.



Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg FibroSleep™ Ultra EPA  - Fish Oil


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health

Natural Remedies

Pioneer Scientists Uncover a Revolutionary Neuroprotective Supplement for Nerve Health Pioneer Scientists Uncover a Revolutionary Neuroprotective Supplement for Nerve Health
Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry
Live Without Anxiety or Stress Live Without Anxiety or Stress
"It's Not Easy Being Green" - But It Is Healthy
The New Dual Activation Pain Relief Cream The New Dual Activation Pain Relief Cream

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map